Dapson in Heterocyclic Chemistry, Part V: Synthesis, Molecular Docking and Anticancer Activity of Some Novel Sulfonylbiscompounds Carrying Biologically Active Dihydropyridine, Dihydroisoquinoline, 1,3-Dithiolan, 1,3-Dithian, Acrylamide, Pyrazole, Pyrazolopyrimidine and Benzochromenemoieties
| dc.Affiliation | October University for modern sciences and Arts (MSA) | |
| dc.contributor.author | Mohammed Ghorab, Mostafa | |
| dc.contributor.author | Sulaiman Al-Said, Mansour | |
| dc.contributor.author | Mohammed Nissan, Yassin | |
| dc.date.accessioned | 2019-10-21T08:03:12Z | |
| dc.date.available | 2019-10-21T08:03:12Z | |
| dc.date.issued | 2012 | |
| dc.description | MSA Google Scholar | |
| dc.description.abstract | N,N′-(4,4′-Sulfonylbis(4,1-phenylene))bis(2-cyanoacetamid) 2 was utilized as a key intermediate for the synthesis of novel dihydropyridines 3, 4, 8, dihydroisoquinolines 5–7, dithiolan 10, dithian 11, acrylamide 12, benzochromenes 17 and 18 and chromenopyridones 19 and 20. Compound 2 was the starting material in the synthesis of the acrylamide derivative 14, the pyrazole derivative 15 and the pyrazolopyrimidine derivative 16. All the synthesized compounds were evaluated for their in vitro anticancer activity against human breast cancer cell line (MCF7). Compound 19 showed the best cytotoxic activity with IC50 value 19.36 μM. In addition, molecular docking study of the synthesized compounds on the active sites of farnesyltransferase and arginine methyltransferase was performed in order to give a suggestion about the mechanism of action of their cytotoxic activity. | en_US |
| dc.description.sponsorship | Chemical and Pharmaceutical Bulletin | en_US |
| dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=22769&tip=sid&clean=0 | |
| dc.identifier.citation | 1) Dominguez J. N., Leon C., Rodrigues J., Gamboa de Dominguez N., Gut J., Rosenthal P. J., Eur. J. Med. Chem., 44, 1457–1462 (2009). 2) Szilágyi G., Somorai T., Bozó É., Langó J., Nagy G., Reiter J., Janáky J., Andrási F., Eur. J. Med. Chem., 25, 95–101 (1990). 3) Gautam N., Goyal K., Saini O., Kumar A., Gautam D. C., J. Fluor. Chem., 132, 420–426 (2011). 4) Bonsignore L., Cottiglia F., Elkhaili H., Jehl F., Lavagna S. M., Loy G., Manna F., Monteil H., Pompei D., Secci D., Farmaco, 53, 425–430 (1998). 5) Usera A. R., Dolan P., Kensler T. W., Posner G. H., Bioorg. Med. Chem., 17, 5627–5631 (2009). 6) Pal T. K., Dey T., Chakrabarty A., Dey D., Ghosh S. K., Pathak T., Bioorg. Med. Chem. Lett., 20, 3777–3780 (2010). 7) Silvestri R., Artico M., La Regina G., De Martino G., La Colla M., Loddo R., La Colla P., Farmaco, 59, 201–210 (2004). 8) Zhang C., Lovering F., Behnke M., Zask A., Sandanayaka V., Sun L., Zhu Y., Xu W., Zhang Y., Levin J. I., Bioorg. Med. Chem. Lett., 19, 3445–3448 (2009). 9) Santelli-Rouvier C., Barret J. M., Farrell C. M., Sharples D., Hill B. T., Barbe J., Eur. J. Med. Chem., 39, 1029–1038 (2004). 10) Murafuji T., Fujiwara Y., Yoshimatsu D., Miyakawa I., Migita K., Mikata Y., Eur. J. Med. Chem., 46, 519–525 (2011). 11) El-Sayed Ali T., Eur. J. Med. Chem., 44, 4385–4392 (2009). 12) Onnis V., Cocco M. T., Fadda R., Congiu C., Bioorg. Med. Chem., 17, 6158–6165 (2009). 13) Karki R., Thapa P., Kang M. J., Jeong T. C., Nam J. M., Kim H. L., Na Y., Cho W. J., Kwon Y., Lee E. S., Bioorg. Med. Chem., 18, 14) Gomez-Monterrey I., Campiglia P., Grieco P., Diurno M. V., Bolognese A., La Colla P., Novellino E., Bioorg. Med. Chem., 11, 3769–3775 (2003). 15) Valderrama J. A., González M. F., Pessoa-Mahana D., Tapia R. A., Fillion H., Pautet F., Rodriguez J. A., Theoduloz C., Schmeda- Hirschmann G., Bioorg. Med. Chem., 14, 5003–5011 (2006). 16) Kast R., Scheuerle A., Wirtz C., Karpel-Massler G., Halatsch M., Anticancer Agents Med. Chem. 11, 756–761 (2011). 17) Bissinger E. M., Heinke R., Spannhoff A., Eberlin A., Metzger E., Cura V., Hassenboehler P., Cavarelli J., Schüle R., Bedford M. T., Sippl W., Jung M., Bioorg. Med. Chem., 19, 3717–3731 (2011). 18) Dinsmore C. J., Williams T. M., O’Neill T. J., Liu D., Rands E., Culberson J. C., Lobell R. B., Koblan K. S., Kohl N. E., Gibbs J. B., Oliff A. I., Graham S. L., Hartman G. D., Bioorg. Med. Chem. Lett., 9, 3301–3306 (1999). 19) Vedula M.S., Pulipaka A. B., Venna C., Chintakunta V. K., Jinnapally S., Kattuboina V. A., Vallakati R. K., Basetti V., Akella V., Rajgopal S., Reka A. K., Teepireddy S. K., Mamnoor P. K., Rajagopalan R., Bulusu G., Khandelwal A., Upreti V. V., RaoMamidi S., Eur. J. Med. Chem., 38, 811–824 (2003). 20) Wadher S. J., Puranik M. P., Karande N. A., Yeole P. G., International Journal of Pharmtech. Research, 1, 22–23 (2009). 21) Ghorab M. M., Radwan M. A. A., Taha N. M. H., Amin N. E., Shehab M. A., Faker I. M. I., Phosphorus Sulfur Silicon Relat. Elem., 183, 2906–2917 (2008). 22) Ghorab M. M., Amin N. E., El Gaby M. S. A., Taha N. M. H., Shehab M. A., Faker I. M. I., Phosphorus Sulfur Silicon Relat. Elem., 183, 2918–2928 (2008). 23) Ghorab M. M., Amin N. E., El Gaby M. S. A., Taha N. M. H., Shehab M. A., Faker I. M. I., Phosphorus Sulfur Silicon Relat. Elem., 183, 2929–2942 (2008). 24) Ghorab M. M., Radwan M. A. A., Taha N. M. H., Amin N. E., Shehab M. A., Faker I. M. I., Phosphorus Sulfur Silicon Relat. Elem., 183, 2891–2905 (2008). 25) Al-Said M. S., Bashandy M. S., Al-Qasoumi S. I., Ghorab M. M., Eur. J. Med. Chem., 46, 137–141 (2011). 26) Leonard D. M., J. Med. Chem., 40, 2971–2990 (1997). 27) Rowinsky E. K., Windle J. J., Von Hoff D. D., J. Clin. Oncol., 17, 3631–3652 (1999). 28) Liu M., Bryant M. S., Chen J., Lee S., Yaremko B., Lipari P., Malkowski M., Ferrari E., Nielsen L., Prioli N., Dell J., Sinha D., Syed J., Korfmacher W. A., Nomeir A. A., Lin C. C., Wang L., Taveras A. G., Doll R. J., Njoroge F. G., Mallams A. K., Remiszewski S., Catino J. J., Girijavallabhan V. M., Bishop W. R., Cancer Res., 58, 4947–4956 (1998). 29) Prendergast G. C., Davide J. P., deSolms S. J., Giuliani E. A., Graham S. L., Gibbs J. B., Oliff A., Kohl N. E., Mol. Cell. Biol., 14, 4193–4202 (1994). 30) Lerner E. C., Qian Y., Blaskovich M. A., Fossum R. D., Vogt A., Sun J., Cox A. D., Der C. J., Hamilton A. D., Sebti S. M., J. Biol. Chem., 270, 26802–26806 (1995). 31) Cox A. D., Der C. J., Biochim. Biophys. Acta, 1333, 51–71 (1997). 32) Lund A. H., van Lohuizen M., Genes Dev., 18, 2315–2335 (2004). 33) Schneider R., Bannister A. J., Kouzarides T., Trends Biochem. Sci., 27, 396–402 (2002). 34) Bedford M. T., Richard S., Mol. Cell, 18, 263–272 (2005). 35) Tang J., Frankel A., Cook R. J., Kim S., Paik W. K., Williams K. R., Clarke S., Herschman H. R., J. Biol. Chem., 275, 7723–7730 (2000). 36) Pawlak M. R., Scherer C. A., Chen J., Roshon M. J., Ruley H. E., Mol. Cell. Biol., 20, 4859–4869 (2000). 37) Herrmann F., Lee J., Bedford M. T., Fackelmayer F. O., J. Biol. Chem., 280, 38005–38010 (2005). 38) Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R., J. Natl. Cancer Inst., 82, 1107–1112 (1990) | en_US |
| dc.identifier.doi | https://doi.org/ | |
| dc.identifier.other | https://doi.org/ | |
| dc.identifier.uri | https://cutt.ly/brX7i5c | |
| dc.language.iso | en | en_US |
| dc.publisher | Chemical and Pharmaceutical Bulletin | en_US |
| dc.relation.ispartofseries | Chem. Pharm. Bull.;60 (8) 1019–1028 | |
| dc.subject | sulfone | en_US |
| dc.subject | pyridine | en_US |
| dc.subject | pyrazolopyrimidine | en_US |
| dc.subject | benzochromene | en_US |
| dc.subject | anticancer activity | en_US |
| dc.title | Dapson in Heterocyclic Chemistry, Part V: Synthesis, Molecular Docking and Anticancer Activity of Some Novel Sulfonylbiscompounds Carrying Biologically Active Dihydropyridine, Dihydroisoquinoline, 1,3-Dithiolan, 1,3-Dithian, Acrylamide, Pyrazole, Pyrazolopyrimidine and Benzochromenemoieties | en_US |
| dc.type | Article | en_US |